UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Intraarterial Hepatic SPECT/CT Imaging Using ^sup 99m^Tc-Macroaggregated Albumin in Preparation for Radioembolization

The Journal of nuclear medicine (1978), 2015-08, Vol.56 (8), p.1157

2015

Volltextzugriff (PDF)

Intraarterial Hepatic SPECT/CT Imaging Using sigma up 99m theta c-Macroaggregated Albumin in Preparation for Radioembolization

The Journal of nuclear medicine (1978), 2015-08, Vol.56 (8), p.1157-1157

2015

Volltextzugriff (PDF)

Intraarterial Hepatic SPECT/CT Imaging Using 99m Tc-Macroaggregated Albumin in Preparation for Radioembolization

Journal of Nuclear Medicine, 2015-08, Vol.56 (8), p.1157-1162

2015

Volltextzugriff (PDF)

Cardiac memory: effects on QT interval and dispersion

Journal of the American College of Cardiology, 2002-03, Vol.39, p.100-100

2002

Volltextzugriff (PDF)

Internal Pair Production of 90 Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept

Journal of Nuclear Medicine, 2011-01, Vol.52 (1), p.72-76

2011

Volltextzugriff (PDF)

Internal Pair Production of ^sup 90^Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept

The Journal of nuclear medicine (1978), 2011-01, Vol.52 (1), p.72

2011

Volltextzugriff (PDF)

W1338 Preliminary Observations of Simultaneous Lactulose Breath Testing (LBT) and Scintigraphy in Controls: SIBO Is Not SIBO

Gastroenterology (New York, N.Y. 1943), 2008, Vol.134 (4), p.A-683-A-683

2008

Volltextzugriff (PDF)

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

Blood, 2010-11, Vol.116 (21), p.1749-1749

2010

Volltextzugriff (PDF)

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with Ytrrium-90 Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin Lymphoma: Pre-Clinical Findings and Results of a Phase I Trial

Clinical cancer research, 2009-10, Vol.15 (20), p.6462-6471

2009

Volltextzugriff (PDF)

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

European journal of nuclear medicine and molecular imaging, 2000-06, Vol.27 (7), p.766-777

2000

Volltextzugriff (PDF)

The use of molecular imaging to predict clinical outcome in patients with rectal cancer after pre-operative chemotherapy and radiation

International journal of radiation oncology, biology, physics, 2008-11, Vol.74 (1), p.55-59

2008

Volltextzugriff (PDF)

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma (NHL)

Blood, 2007-11, Vol.110 (11), p.2558-2558

2007

Volltextzugriff (PDF)

Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia

Cancer biotherapy & radiopharmaceuticals, 2004-08, Vol.19 (4), p.478-481

2004

Volltextzugriff (PDF)

P-429 FDG-positron emission tomography scanning(PET) in the staging and monitoring of small cell lung cancer(SCLC)

Lung cancer (Amsterdam, Netherlands), 2003-08, Vol.41, p.S200-S200

2003

Volltextzugriff (PDF)

Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin®; 90Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non- Hodgkin's Lymphoma (NHL)

Blood, 2005-11, Vol.106 (11), p.2450-2450

2005

Volltextzugriff (PDF)

Feasibility of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy for Non-Hodgkin's Lymphoma in a Patient with Chronic Renal Failure

Blood, 2004-11, Vol.104 (11), p.4642-4642

2004

Volltextzugriff (PDF)

Nuclear Scanning With Technetium-99m-Sestamibi to Evaluate Ischemia in Muscle Flaps for Cardiomyoplasty

ASAIO journal (1992), 1995-07, Vol.41 (3), p.M508-M511

1995

Volltextzugriff (PDF)

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma

Seminars in oncology, 2002-02, Vol.29 (1S2), p.87

2002

Volltextzugriff (PDF)

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL

Blood, 2006-11, Vol.108 (11), p.330-330

2006

Volltextzugriff (PDF)

Left ventricular function during and after right ventricular pacing. Commentary

Journal of the American College of Cardiology, 2004, Vol.44 (9), p.1883-1890

2004

Volltextzugriff (PDF)

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry

Blood, 2004-11, Vol.104 (11), p.1162-1162

2004

Volltextzugriff (PDF)

Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-HodgkinÕs Lymphoma and Mild Thrombocytopenia

Cancer biotherapy & radiopharmaceuticals, 2004-08, Vol.19 (4), p.478

2004

Volltextzugriff (PDF)

CONSIDERATIONS IN CALCULATION OF LEFT VENTRICULAR EJECTION FRACTION FROM GATED BLOOD POOL STUDIES

Investigative radiology, 1981-09, Vol.16 (5), p.400-400

1981

Volltextzugriff (PDF)

Association between african american race/ethnicity and low bone mineral density in women with systemic lupus erythematosus : Disparities in rheumatic diseases

Arthritis care and research, 2007, Vol.57 (4), p.585-592

2007

Volltextzugriff (PDF)

The Effect of Remifentanil on Biliary Tract Drainage into the Duodenum

Anesthesia and analgesia, 1999-12, Vol.89 (6), p.1561

1999

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Englisch
(65)
Japanisch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Intraarterial Hepatic SPECT/CT Imaging Using ^sup 99m^Tc-Macroaggregated Albumin in Preparation for Radioembolization

Intraarterial Hepatic SPECT/CT Imaging Using sigma up 99m theta c-Macroaggregated Albumin in Preparation for Radioembolization

Intraarterial Hepatic SPECT/CT Imaging Using 99m Tc-Macroaggregated Albumin in Preparation for Radioembolization

Cardiac memory: effects on QT interval and dispersion

Internal Pair Production of 90 Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept

Internal Pair Production of ^sup 90^Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept

W1338 Preliminary Observations of Simultaneous Lactulose Breath Testing (LBT) and Scintigraphy in Controls: SIBO Is Not SIBO

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with Ytrrium-90 Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin Lymphoma: Pre-Clinical Findings and Results of a Phase I Trial

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

The use of molecular imaging to predict clinical outcome in patients with rectal cancer after pre-operative chemotherapy and radiation

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma (NHL)

Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia

P-429 FDG-positron emission tomography scanning(PET) in the staging and monitoring of small cell lung cancer(SCLC)

Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin®; 90Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non- Hodgkin's Lymphoma (NHL)

Feasibility of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy for Non-Hodgkin's Lymphoma in a Patient with Chronic Renal Failure

Nuclear Scanning With Technetium-99m-Sestamibi to Evaluate Ischemia in Muscle Flaps for Cardiomyoplasty

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL

Left ventricular function during and after right ventricular pacing. Commentary

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry

Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-HodgkinÕs Lymphoma and Mild Thrombocytopenia

CONSIDERATIONS IN CALCULATION OF LEFT VENTRICULAR EJECTION FRACTION FROM GATED BLOOD POOL STUDIES

Association between african american race/ethnicity and low bone mineral density in women with systemic lupus erythematosus : Disparities in rheumatic diseases

The Effect of Remifentanil on Biliary Tract Drainage into the Duodenum

Aktive Filter

Suchergebnisse filtern